Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh 11461, Kingdom of Saudi Arabia.
Colorectal Research Center, Department of Surgery, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Cell Death Dis. 2015 Jan 22;6(1):e1614. doi: 10.1038/cddis.2014.556.
Despite recent advances in cancer management, colorectal cancer (CRC) remains the third most common cancer and a major health-care problem worldwide. MicroRNAs have recently emerged as key regulators of cancer development and progression by targeting multiple cancer-related genes; however, such regulatory networks are not well characterized in CRC. Thus, the aim of this study was to perform global messenger RNA (mRNA) and microRNA expression profiling in the same CRC samples and adjacent normal tissues and to identify potential miRNA-mRNA regulatory networks. Our data revealed 1273 significantly upregulated and 1902 downregulated genes in CRC. Pathway analysis revealed significant enrichment in cell cycle, integrated cancer, Wnt (wingless-type MMTV integration site family member), matrix metalloproteinase, and TGF-β pathways in CRC. Pharmacological inhibition of Wnt (using XAV939 or IWP-2) or TGF-β (using SB-431542) pathways led to dose- and time-dependent inhibition of CRC cell growth. Similarly, our data revealed up- (42) and downregulated (61) microRNAs in the same matched samples. Using target prediction and bioinformatics, ~77% of the upregulated genes were predicted to be targeted by microRNAs found to be downregulated in CRC. We subsequently focused on EZH2 (enhancer of zeste homolog 2 ), which was found to be regulated by hsa-miR-26a-5p and several members of the let-7 (lethal-7) family in CRC. Significant inverse correlation between EZH2 and hsa-miR-26a-5p (R(2)=0.56, P=0.0001) and hsa-let-7b-5p (R(2)=0.19, P=0.02) expression was observed in the same samples, corroborating the belief of EZH2 being a bona fide target for these two miRNAs in CRC. Pharmacological inhibition of EZH2 led to significant reduction in trimethylated histone H3 on lysine 27 (H3K27) methylation, marked reduction in cell proliferation, and migration in vitro. Concordantly, small interfering RNA-mediated knockdown of EZH2 led to similar effects on CRC cell growth in vitro. Therefore, our data have revealed several hundred potential miRNA-mRNA regulatory networks in CRC and suggest targeting relevant networks as potential therapeutic strategy for CRC.
尽管癌症治疗在最近取得了进展,但结直肠癌(CRC)仍然是全球第三大常见癌症和主要的医疗保健问题。MicroRNAs 最近成为癌症发生和发展的关键调节剂,通过靶向多个与癌症相关的基因;然而,CRC 中的这种调节网络尚未得到很好的描述。因此,本研究的目的是在相同的 CRC 样本和相邻正常组织中进行全局信使 RNA(mRNA)和 microRNA 表达谱分析,并鉴定潜在的 miRNA-mRNA 调节网络。我们的数据显示,CRC 中有 1273 个显著上调和 1902 个下调基因。通路分析显示,CRC 中细胞周期、整合癌症、Wnt(无翅型 MMV 整合位点家族成员)、基质金属蛋白酶和 TGF-β 通路明显富集。Wnt(使用 XAV939 或 IWP-2)或 TGF-β(使用 SB-431542)途径的药理学抑制导致 CRC 细胞生长呈剂量和时间依赖性抑制。同样,我们的数据显示,在相同的匹配样本中,上调(42)和下调(61)microRNAs。使用靶预测和生物信息学,发现上调基因的~77%被在 CRC 中下调的 microRNAs 靶向。随后,我们将重点放在 EZH2(增强子 of zeste 同源物 2)上,发现其在 CRC 中受 hsa-miR-26a-5p 和几个 let-7(致命-7)家族成员的调控。在相同的样本中观察到 EZH2 与 hsa-miR-26a-5p(R(2)=0.56,P=0.0001)和 hsa-let-7b-5p(R(2)=0.19,P=0.02)表达之间存在显著的负相关,这证实了 EZH2 是这两个 miRNA 在 CRC 中的真正靶标。EZH2 的药理学抑制导致三甲基化组蛋白 H3 赖氨酸 27 上的 H3K27 甲基化显著减少,体外细胞增殖和迁移显著减少。同样,CRC 细胞生长的体外实验也表明,用小干扰 RNA 介导的 EZH2 敲低会产生类似的影响。因此,我们的数据揭示了 CRC 中数百个潜在的 miRNA-mRNA 调节网络,并表明靶向相关网络可能是 CRC 的潜在治疗策略。